Attachment of the soluble complement regulator factor H to cell and tissue surfaces: Relevance for pathology

Histology and Histopathology

Volumn 19, Issue 1, 2004, Pages 251-258

  Jozsi M ^a   Manuelian, T ^a   Heinen, S ^a   Oppermann, M ^b   Zipfel, Peter F ^a  

^a HANS KNÖLL INSTITUTE   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Cellular binding; Disease mechanisms; Hemolytic uremic syndrome; Immune defense; Innate immunity

Indexed keywords

COMPLEMENT FACTOR H;

CARBOXY TERMINAL SEQUENCE; CELL SURFACE; CHRONIC INFLAMMATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT FACTOR; DEFENSE MECHANISM; DISEASE ASSOCIATION; ENDOTHELIUM CELL; FLOW CYTOMETRY; GENE MUTATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOFLUORESCENCE MICROSCOPY; INFECTION; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MICROBIAL GROWTH; PATHOPHYSIOLOGY; REGULATORY MECHANISM; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; BINDING SITES; CELL LINE; COMPLEMENT ACTIVATION; COMPLEMENT C3B; COMPLEMENT FACTOR H; COMPLEMENT PATHWAY, ALTERNATIVE; ENDOTHELIUM, VASCULAR; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNITY, NATURAL; MODELS, BIOLOGICAL; PATHOLOGY; POINT MUTATION; SOLUBILITY; SURFACE PROPERTIES; UMBILICAL VEINS;

EID: 1642518600     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Ault B.H., Schmidt B.Z., Fowler N.L., Kashtan C.E., Ahmed A.E., Vogt B.A. and Colten H.R. (1997). Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism. J. Biol. Chem. 272, 25168-25175.
2. Blackmore T.K., Sadlon T.A., Ward H.M., Lublin D.M. and Gordon D.L. (1996). Identification of a heparin binding domain in the seventh short consensus repeat of complement factor H. J. Immunol. 157, 5422-5427.
3. Blackmore T.K., Hellwage J., Sadlon T.A., Higgs N., Zipfel P.F., Ward H.M. and Gordon D.L. (1998). Identification of the second heparin-binding domain in human complement factor H. J. Immunol. 160, 3342-3348.
4. Caprioli J., Bettinaglio P., Zipfel P.F., Amadei B., Daina E., Gamba S., Skerka C., Marziliano N., Remuzzi G. and Noris M. (2001). The molecular basis of familial haemolytic uremic syndrome: Mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J. Am. Soc. Nephrol. 12, 297-307.
5. Carreno M.P., Labarre D., Maillet F., Jozefowicz M. and Kazatchkine M.D. (1989). Regulation of the human alternative complement pathway: Formation of a ternary complex between factor H, surface-bound C3b and chemical groups on nonactivating surfaces. Eur. J. Immunol. 19, 2145-2150.
6. Devine D.V. and Rosse W.F. (1987). Regulation of the activity of platelet-bound C3 convertase of the alternative pathway of complement by platelet factor H. Proc. Natl. Acad. Sci. USA 84, 5873-5877.
7. Devine D.V., Siegel R.S. and Rosse W.F. (1987). Interactions of the platelets in paroxysmal nocturnal hemoglobinuria with complement. Relationship to defects in the regulation of complement and to platelet survival in vivo. J. Clin. Invest. 79, 131-137.
8. DiScipio R.G., Daffern P.J., Schraufstatter I.U. and Sriramarao P. (1998). Human polymorphonuclear leukocytes adhere to complement factor H through an interaction that involves alphaMbeta2 (CD11b/CD18). J. Immunol. 160, 4057-4066.
9. Fedarko N.S., Fohr B., Robey P.G., Young M.F. and Fisher L.W. (2000). Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J. Biol. Chem. 275, 16666-16672.
10. Friese M.A., Hellwage J., Jokiranta T.S., Meri S., Peter H.H., Eibel H. and Zipfel P.F. (1999). FHL-1/reconectin and factor H: Two human complement regulators which are encoded by the same gene are differently expressed and regulated. Mol. Immunol. 36, 809-818.
11. Friese M.A., Hellwage J., Jokiranta T.S., Meri S., Muller-Quernheim H.J., Peter H.H., Eibel H. and Zipfel P.F. (2000). Different regulation of factor H and FHL-1/reconectin by inflammatory mediators and expression of the two proteins in rheumatoid arthritis (RA). Clin. Exp. Immunol. 121, 406-415.
12. Friese M.A., Manuelian T., Junnikkala S., Hellwage J., Meri S., Peter H.H., Gordon D.L., Eibel H. and Zipfel P.F. (2003). Release of endogenous anti-inflammatory complement regulators FHL-1 and factor H protects synovial fibroblasts during rheumatoid arthritis. Clin. Exp. Immunol. 132, 485-495.
13. Hegasy G.A., Manuelian T., Hogasen K., Jansen J.H. and Zipfel P.F. (2002). The molecular basis for hereditary porcine membranoproliferative glomerulonephritis type II: Point mutations in the factor H coding sequence block protein secretion. Am. J. Pathol. 161, 2027-2034.
14. Hellwage J., Jokiranta T.S., Friese M.A., Wolk T.U., Kampen E., Zipfel P.F. and Meri S. (2002). Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxyl-terminal domain of complement factor H. J. Immunol. 169, 6935-6944.
15. Hogasen K., Jansen J.H., Mollnes T.E., Hovdenes J. and Harboe M. (1995). Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J. Clin. Invest. 95, 1054-1061.
16. Jain A., Karadag A., Fohr B., Fisher L.W. and Fedarko N.S. (2002). Three SIBLINGs (small integrin-binding ligand, N-linked glycoproteins) enhance factor H's cofactor activity enabling MCP-like cellular evasion of complement-mediated attack. J. Biol. Chem. 277, 13700-13708.
17. Jokiranta T.S., Solomon A., Pangburn M.K., Zipfel P.F. and Meri S. (1999). Nephritogenic lambda light chain dimer: A unique human miniautoantibody against complement factor H. J. Immunol. 163, 4590-4596.
18. Junnikkala S., Jokiranta T.S., Friese M.A., Jarva H., Zipfel P.F. and Meri S. (2000). Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J. Immunol. 164, 6075-6081.
19. Junnikkala S., Hakulinen J., Jarva H., Manuelian T., Bjorge L., Butzow R., Zipfel P.F. and Meri S. (2002). Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. Br. J. Cancer 87, 1119-1127.
20. Kazatchkine M.D., Fearon D.T. and Austen K.F. (1979). Human alternative complement pathway: Membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J. Immunol. 122, 75-81.
21. Kemper C., Zipfel P.F. and Gigli I. (1998). The complement cofactor protein (SBP1) from the barred and bass (Paralabrax nebulifer) mediates overlapping regulatory activities of both human C4b binding protein and factor H. J. Biol. Chem. 273, 19398-19404.
22. Klickstein L.B. and Moulds J.M. (2000). CR1. In: The Complement FactsBook. Morley B.J. and Walport M.J. (eds). Academic Press. pp. 136-145.
23. Krushkal J., Bat O. and Gigli I. (2000). Evolutionary relationships among proteins encoded by the regulator of complement activation gene cluster. Mol. Biol. Evol. 17, 1718-1730.
24. Kuttner-Kondo L., Brodbeck W.G. and Medof M.F. (2000). Decay accelerating factor. In: The Complement FactsBook. Morley B.J. and Walport M.J. (eds). Academic Press. pp 152-155.
25. Landau D., Shalev H., Levy-Finer G., Polonsky A., Segev Y.a nd Katchko L. (2001). Familial hemolytic uremic syndrome associated with complement factor H deficiency. J. Pediatr. 138, 412-417.
26. Liszewski M.K. and Atkinson J.P. (2000). Membrane cofactor protein. In: The Complement FactsBook. Morley B.J. and Walport M.J. (eds). Academic Press. pp 156-160.
27. Manuelian T., Hellwage J., Meri S., Caprioli J., Noris M., Heinen S., Józsi M., Neumann H.P., Remuzzi G. and Zipfel P.F. (2003). Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J. Clin. Invest. 111, 1181-1190.
28. Martinez A., Pio R., Zipfel P.F. and Cuttitta F. (2003). Mapping of the adrenomedullin-binding domains in human complement factor H. Hypertens. Res. 26 Suppl., S55-S59.
29. Mathieson P. (2002). Complement factor H and haemolytic uraemic syndrome. Lancet 359, 801-802.
30. Meri S. and Pangburn M.K. (1990). Discrimination between activators and nonactivators of the alternative pathway of complement: Regulation via a sialic acid/polyanion binding site of factor H. Proc. Natl. Acad. Sci. USA 87, 3982-3986.
31. Meri S., Koistinen V., Miettinen A., Tornroth T. and Seppala I.J. (1992). Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J. Exp. Med. 175, 939-950.
32. Morgan B.P. and Harris C.L. (1999). Complement Regulatory Proteins. Academic Press.
33. Nabil K., Rihn B., Jaurand M.C., Vignaud J.M., Ripoche J., Martinet Y. and Martinet N. (1997). Identification of human complement factor H as a chemotactic protein for monocytes. Biochem. J. 326, 377-383.
34. Noris M., Ruggenenti P., Perna A., Orisio S., Caprioli J., Skerka C., Vasile B., Zipfel P.F. and Remuzzi G. (1999). Hypocomplementemia discloses genetic predisposition to hemolytic uremic syndrome and thrombotic thrombocytopenia purpura: Role of factor H abnormalities. Italian Registry of Familial and Recurrent Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. J. Am. Soc. Nephrol. 10, 281-293.
35. Pangburn M.K. (2002). Cutting edge: Localization of the host recognition functions of complement factor H at the carboxyl-terminal: Implications for hemolytic uremic syndrome. J. Immunol. 169, 4702-4706.
36. Pangburn M.K., Atkinson M.A. and Meri S. (1991). Localization of the heparin-binding site on complement factor H. J. Biol. Chem. 266, 16847-16853.
37. Pérez-Caballero D., González-Rubio C., Gallardo M.E., Vera M., López-Trascasa M., Rodríguez De Córdoba S. and Sánchez-Corral P. (2001). Clustering of missence mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am. J. Hum. Genet. 68, 478-484.
38. Perkins S.J., Gilbert H.E., Aslam M., Hannan J., Holers V.M. and Goodship T.H. (2002). Solution structures of complement components by X-ray and neutron scattering and analytical ultracentrifugation. Biochem. Soc. Trans. 30, 996-1006.
39. Pichette V., Querin S., Schurch W., Brun G., Lehner-Netsch G. and Delage J.M. (1994). Familial hemolytic-uremic syndrome and homozygous factor H deficiency. Am. J. Kidney Dis. 24, 936-941.
40. Pickering M.C., Cook H.T., Warren J., Bygrave A.E., Moss J., Walport M.J. and Botto M. (2002). Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat. Genet. 31, 424-428.
41. Pio R., Martinez A., Unsworth E.J., Kowalak J.A., Bengoechea J.A., Zipfel P.F., Elsasser T.H. and Cuttitta F. (2001). Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners. J. Biol. Chem. 276, 12292-12300.
42. Ram S., Sharma A.K., Simpson S.D., Gulati S., McQuillen D.P., Pangburn M.K. and Rice P.A. (1998). A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae. J. Exp. Med. 187, 743-752.
43. Richards A., Buddles M.R., Donne R.L., Kaplan B.S., Kirk E., Venning M.C., Tielemans C.L., Goodship J.A. and Goodship T.H.J. (2001). Factor H mutations in haemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am. J. Hum. Genet. 68, 485-490.
44. Sánchez-Corral P., Pérez-Caballero D., Huarte O., Simckes A.M., Goicoechea E., López-Trascasa M. and De Córdoba S.R. (2002). Structural and functional characterization of factor H mutations associated with atypical hemolytic uremic syndrome. Am. J. Hum. Genet. 71, 1285-1295.
45. Schlaf G., Demberg T., Beisel N., Schieferdecker H.L. and Gotze O. (2001). Expression and regulation of complement factors H and I in rat and human cells: Some critical notes. Mol. Immunol. 38, 231-239.
46. Taylor C.M. (2001). Complement factor H and the haemolytic uraemic syndrome. Lancet 358, 1200-1202.
47. Thompson R.A. and Winterborn M.H. (1981). Hypocomplementaemia due to a genetic deficiency of b1H globulin. Clin. Exp. Immunol. 46, 110-119.
48. Walport M.J. (2001a). Complement. First of two parts. N. Engl. J. Med. 344, 1058-1066.
49. Walport M.J. (2001b). Complement. Second of two parts. N. Engl. J. Med. 344, 1140-1144.
50. Warwicker P., Donne R.L., Goodship J.A., Goodship T.H., Howie A.J., Kumararatne D.S., Thompson R.A. and Taylor C.M. (1999). Familial relapsing haemolytic uraemic syndrome and complement factor H deficiency. Nephrol. Dial. Transplant. 14, 1229-1233.
51. Zipfel P.F. (2001). Hemolytic uremic syndrome: How do factor H mutants mediate endothelial damage? Trends Immunol. 22, 345-348.
52. Zipfel P.F., Hellwage J., Friese M.A., Hegasy G., Jokiranta S.T. and Meri S. (1999). Factor H and disease: A complement regulator affects vital body functions. Mol. Immunol. 36, 241-248.